Formulation And Evaluation Of Fast Acting Tablets Of Anti Psychotic Drug By Liquisolid Technique

Abstract

Clozapine, a BCS Class II atypical antipsychotic drug, suffers from poor aqueous solubility and extensive first-pass metabolism, leading to low oral bioavailability. The liquisolid technique offers a promising approach for improving solubility and dissolution of such poorly soluble drugs through molecular dispersion over suitable carriers. The study aimed to formulate and evaluate fast-acting orally disintegrating tablets (ODTs) of clozapine using the liquisolid approach with oil-free peanut powder as a novel, natural carrier material to enhance dissolution rate and patient compliance. Clozapine was dissolved in polyethylene glycol 400 (PEG 400) and adsorbed onto oil-free peanut powder. The liquisolid system was further formulated into ODTs and evaluated for pre- and post-compression parameters, including micromeritic properties, hardness, friability, disintegration time, and in-vitro dissolution. FTIR, DSC, and SEM analyses were conducted to assess compatibility and surface morphology. Optimization was performed using a 3² factorial design varying binder and disintegrant concentrations. The optimized batch (25-F15) exhibited disintegration within 20 seconds and drug release >100% within 9 minutes, significantly outperforming the marketed Sizopin 25™ tablets. FTIR and DSC confirmed no chemical incompatibility, and SEM images demonstrated a uniform coating of clozapine on the porous peanut powder carrier, indicating successful molecular dispersion. The use of oil-free peanut powder as a carrier in the liquisolid system proved highly effective for enhancing the solubility and dissolution rate of clozapine. The technique is simple, scalable, and cost-efficient, showing potential for industrial application in developing fast-acting oral formulations of poorly soluble drugs.